Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most drug–interaction and harm-type assertions are broadly consistent with the label’s warnings that interacting drugs can increase statin concentrations and raise myopathy/rhabdomyolysis and liver risks, and that grapefruit juice and specific interacting drugs affect atorvastatin exposure. However, several claims are overly specific or generalized beyond what the provided label excerpts explicitly support (notably kidney-problem risk and warfarin bleeding).
Category Scores
Accurate Statements
Lipitor (atorvastatin) is used to prevent cardiovascular disease.
Indications 1.1 Prevention of Cardiovascular Disease (reduces risk of MI, stroke, revascularization/angina; includes patients with CHD or multiple risk factors).
Grapefruit juice can increase Lipitor levels in the bloodstream.
Drug Interactions 7: Grapefruit Juice can increase plasma concentrations of atorvastatin (especially with excessive grapefruit juice consumption >1.2 liters/day).
Erythromycin taken with Lipitor can increase Lipitor levels in the bloodstream.
Drug Interactions 7 excerpt includes strong CYP3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, itraconazole). The provided excerpts do not explicitly mention erythromycin; therefore this is not label-supported as written. (See unsupported below.)
Colchicine taken with Lipitor can increase the risk of muscle damage.
The provided Drug Interactions and Warnings excerpts mention increased risk of myopathy/rhabdomyolysis with certain drugs (e.g., cyclosporine, clarithromycin/strong CYP3A4 inhibitors) and general statin myopathy risk, but do not mention colchicine specifically in the provided excerpts.
Unsupported Statements
Lipitor (atorvastatin) is used to lower cholesterol levels.
The provided label excerpts explicitly describe lowering elevated lipid parameters (e.g., total-C, LDL-C, TG) in Hyperlipidemia (1.2), but the claim is overly general and not tied to the label’s wording ('indicated ... to reduce elevated total-C, LDL-C, apo B, and TG...').
Grapefruit juice can increase the risk of liver damage.
While liver dysfunction monitoring and liver injury risk are described in general (Warnings 5.2; Postmarketing includes hepatic failure), the provided grapefruit-juice interaction excerpt only states increased plasma concentrations of atorvastatin, not a grapefruit-juice–specific liver damage risk.
Grapefruit juice can increase the risk of kidney problems.
The provided Warnings 5.1 describe rhabdomyolysis with acute renal failure secondary to myoglobinuria, but the provided grapefruit-juice interaction excerpt does not explicitly link grapefruit juice to kidney problems.
Warfarin taken with Lipitor can increase the risk of bleeding.
The provided Drug Interactions excerpt lists cyclosporine, clarithromycin, protease inhibitors, itraconazole, grapefruit juice, and cyclosporine dose limits, but does not mention warfarin.
Cyclosporine taken with Lipitor can increase the risk of kidney damage.
The provided label excerpts state cyclosporine increases risk of myopathy/rhabdomyolysis and includes a cyclosporine dose limit (not exceeding 10 mg), but do not explicitly state 'kidney damage' as a cyclosporine-specific interaction in the provided excerpt.
Erythromycin taken with Lipitor can increase Lipitor levels in the bloodstream.
The provided Drug Interactions excerpt includes clarithromycin as an example of a strong CYP3A4 inhibitor; erythromycin is not explicitly mentioned.
Increased Lipitor levels from erythromycin can increase the risk of side effects.
While increased plasma concentrations are discussed generally for CYP3A4 inhibitors, the provided excerpt does not explicitly mention erythromycin nor link it to side effects.
Colchicine taken with Lipitor can increase the risk of muscle damage.
The provided excerpts do not mention colchicine.
Lipitor interactions can lead to liver damage.
The label excerpts describe liver dysfunction as a known concern and monitoring recommendations, but the provided interaction excerpts do not state that 'interactions' specifically cause liver damage.
Lipitor interactions can lead to kidney damage.
The label excerpt supports that rhabdomyolysis can involve acute renal failure secondary to myoglobinuria, but does not support a general statement that 'interactions' can lead to kidney damage (as opposed to specifically increased myopathy risk).
Lipitor interactions can increase the risk of bleeding.
The provided excerpts include a note about hemorrhagic stroke incidence in SPARCL for high-dose atorvastatin, but do not support that drug interactions increase bleeding risk.
Taking Lipitor with warfarin is not recommended because it can increase the risk of bleeding.
Warfarin is not addressed in the provided Drug Interactions excerpt; no label basis is included here.
Taking Lipitor with cyclosporine is not recommended because it can increase the risk of kidney damage.
The label excerpt provided does not explicitly state 'not recommended' and does not explicitly connect cyclosporine to kidney damage; it discusses limiting dose to 10 mg and increased risk of myopathy/rhabdomyolysis.
Taking Lipitor with erythromycin is not recommended because it can increase Lipitor levels in the bloodstream and increase the risk of side effects.
Erythromycin is not included in the provided Drug Interactions excerpt; the label supports clarithromycin as an example of strong CYP3A4 inhibitor with caution at higher doses.
Taking Lipitor with colchicine is not recommended because it can increase the risk of muscle damage.
Colchicine is not mentioned in the provided excerpts.
Contradictions
Low
AI Statement
Taking Lipitor with grapefruit juice is not recommended because it can increase Lipitor levels in the bloodstream and increase the risk of side effects.
Label Reference
Drug Interactions 7: grapefruit juice can increase plasma concentrations of atorvastatin; label specifies especially with excessive consumption (>1.2 liters/day).
Important Omissions
Dose-specific grapefruit juice guidance: the label excerpt specifies increased concentrations especially with excessive grapefruit juice consumption (>1.2 liters/day), which is not reflected in the claim.
Importance:
Moderate
Cyclosporine dosing restriction details (limit atorvastatin to 10 mg once daily) and clarithromycin/itraconazole/protease-inhibitor 'dose exceeds 20 mg' caution; the response uses generalized 'not recommended' language.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several interaction statements are not supported by the provided label excerpts (notably warfarin bleeding, colchicine, erythromycin, and generalized kidney/liver/bleeding risk), which could mislead safety assessment. At least the grapefruit juice exposure effect and statin myopathy/rhabdomyolysis concept align with the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims about specific interacting drugs and specific organ risks (warfarin bleeding; erythromycin; colchicine; grapefruit juice causing kidney/liver damage; generalized liver/kidney/bleeding from 'interactions') are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict interaction claims to the provided label’s supported examples and wording: grapefruit juice increases atorvastatin plasma concentrations (especially with >1.2 L/day), statin myopathy/rhabdomyolysis risk increases with drugs including cyclosporine and strong CYP3A4 inhibitors (clarithromycin, itraconazole), and include label-specific dose limits/caution thresholds (e.g., cyclosporine limit 10 mg; caution when atorvastatin dose exceeds 20 mg with certain inhibitors) rather than blanket 'not recommended' and specific bleeding/kidney/liver outcomes not explicitly stated in the excerpts.